Comparison of risk of peritoneal dialysis-associated peritonitis between roxadustat and recombinant human erythropoietin in peritoneal dialysis patients: a retrospective comparative cohort study

BACKGROUND: Roxadustat and recombinant human erythropoietin (rhuEPO) have been approved for the treatment of renal anemia in patients undergoing dialysis. The comparison of risk of peritoneal dialysis (PD)-associated peritonitis between roxadustat and rhuEPO in PD patients remains uncertain. We aime...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wei, Tan, Yanhong, Ai, Jun, Luo, Fuzhang, Su, Xiaoyan, Wu, Qimeng, Su, Lijuan, Pan, Jianyi, Zheng, Qingkun, Li, Bin, Chen, Jiayi, Luo, Qimei, Chen, Jinzhong, Dou, Xianrui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761165/
https://www.ncbi.nlm.nih.gov/pubmed/36544662
http://dx.doi.org/10.21037/atm-22-5050

Ejemplares similares

Ejemplares similares